Top

Reviews in Endocrine and Metabolic Disorders

Published in:

Open Access 01-02-2022 | Lipolysis

Metabolic responses of light and taste receptors – unexpected actions of GPCRs in adipocytes

Authors: Onyinye Nuella Ekechukwu, Mark Christian

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2022

Abstract

The G-protein-coupled receptor (GPCR) superfamily includes sensory receptors that can detect and respond to taste and light. Recent investigations have identified key metabolic roles for such receptors in tissues considered ‘non-sensory’ such as adipose tissue. The major functions of white and brown adipose tissues include energy storage/release and thermogenesis, respectively. These processes are tightly controlled by GPCR pathways that serve to maintain energy homeostasis. Opsins 3 and 4 are GPCRs activated by blue light and in adipocytes control lipolysis as well as affect brown adipocyte activity. Furthermore, Opsin 3 signals to regulate the conversion of white to thermogenic beige/BRITE (Brown-in-white) adipocytes. Taste receptors that respond to fatty acids, sweet and bitter are expressed in adipocytes as well as in taste buds. Ffar2 and the long chain fatty acid receptor GPR120 are highly expressed in white adipocytes and the human tongue. In adipose tissue Ffar2 mediates the metabolic effects of butyrate and propionate produced by the gut microbiome. GPR120 is highly expressed in brown adipose tissue and regulates fatty acid oxidation and mitochondrial function. The type I taste receptor Tas1r3 senses sweet and umami, is expressed in adipocytes and on obesogenic diets Tas1r3 global gene knockout protects from metabolic dysfunction. Type II taste receptors that sense bitter are expressed by adipocytes and bitter agonists have been found to modulate adipocyte differentiation and lipid storage levels. This review explores recent unexpected findings of light and taste receptors in adipocytes and examines effects of their signaling in the control of adipose tissue biology.

MacDougald OA, Burant CF. The Rapidly Expanding Family of Adipokines. Cell Metab. Cell Metab. 2007. p. 159–61. Available from: https://pubmed.ncbi.nlm.nih.gov/17767903/.

Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: An endocrine organ. Arch Med Sci. Termedia Publishing; 2013. p. 191–200. Available from: /pmc/articles/PMC3648822/.

Giralt M, Villarroya F. White, brown, beige/brite: Different adipose cells for different functions? Endocrinology. Endocrinology; 2013. p. 2992–3000. Available from: https://pubmed.ncbi.nlm.nih.gov/23782940/.

Amisten S, Neville M, Hawkes R, Persaud SJ, Karpe F, Salehi A. An atlas of G-protein coupled receptor expression and function in human subcutaneous adipose tissue. Pharmacol Ther. Elsevier BV; 2015;146:61–93. Available from: https://pubmed.ncbi.nlm.nih.gov/25242198/.

Im H, Park JH, Im S, Han J, Kim K, Lee YH. Regulatory roles of G-protein coupled receptors in adipose tissue metabolism and their therapeutic potential. Arch Pharm Res. Pharmaceutical Society of Korea; 2021. p. 133–45. Available from: https://pubmed.ncbi.nlm.nih.gov/33550564/.

Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. MDPI AG; 2019;20. Available from: /pmc/articles/PMC6539070/.

van Diepen JA, Robben JH, Hooiveld GJ, Carmone C, Alsady M, Boutens L, et al. SUCNR1-mediated chemotaxis of macrophages aggravates obesity-induced inflammation and diabetes. Diabetologia. Springer Verlag; 2017;60:1304–13. Available from: https://pubmed.ncbi.nlm.nih.gov/28382382/.

Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. W.B. Saunders; 2019;92:6–10. Available from: https://pubmed.ncbi.nlm.nih.gov/30253139/.

Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci. The Company of Biologists Ltd; 2003;116:4867–9. Available from: http://pdsp.cwru.edu.

10.

Hanlon CD, Andrew DJ. Outside-in signaling - A brief review of GPCR signaling with a focus on the Drosophila GPCR family. J Cell Sci. Company of Biologists Ltd; 2015. p. 3533–42. Available from: https://pubmed.ncbi.nlm.nih.gov/26345366/.

11.

Hepler JR, Gilman AG. G proteins. Trends Biochem Sci. Trends Biochem Sci; 1992;17:383–7. Available from: https://pubmed.ncbi.nlm.nih.gov/1455506/.

12.

Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. NIH Public Access; 2009. p. 356–63. Available from: /pmc/articles/PMC3967846/.

13.

Cannon B, Nedergaard J. Brown Adipose Tissue: Function and Physiological Significance. Physiol Rev. 2004;84:277–359.CrossRef

14.

Cao W, Daniel KW, Robidoux J, Puigserver P, Medvedev AV, Bai X, et al. p38 Mitogen-Activated Protein Kinase Is the Central Regulator of Cyclic AMP-Dependent Transcription of the Brown Fat Uncoupling Protein 1 Gene. Mol Cell Biol. Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA.; 2004;24:3057–67. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15024092.

15.

Rosenwald M, Perdikari A, Rülicke T, Wolfrum C. Bi-directional interconversion of brite and white adipocytes. Nat Cell Biol. Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland.; 2013;15:659–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23624403.

16.

Kim SH, Plutzky J. Brown fat and browning for the treatment of obesity and related metabolic disorders. Diabetes Metab J. Korean Diabetes Association; 2016. p. 12–21. Available from: https://pubmed.ncbi.nlm.nih.gov/26912151/.

17.

Nayak G, Zhang KX, Vemaraju S, Odaka Y, Buhr ED, Holt-Jones A, et al. Adaptive Thermogenesis in Mice Is Enhanced by Opsin 3-Dependent Adipocyte Light Sensing. Cell Rep. Elsevier B.V.; 2020;30:672–686.e8. Available from: https://pubmed.ncbi.nlm.nih.gov/31968245/.

18.

Choi MS, Kim YJ, Kwon EY, Ryoo JY, Kim SR, Jung UJ. High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflamm. Br J Nutr. Cambridge University Press; 2015;113:867–77. Available from: https://pubmed.ncbi.nlm.nih.gov/25744306/.

19.

Sato M, Tsuji T, Yang K, Ren X, Dreyfuss JM, Huang TL, et al. Cell-autonomous light sensitivity via Opsin3 regulates fuel utilization in brown adipocytes. PLoS Biol. Public Library of Science; 2020;18. Available from: https://pubmed.ncbi.nlm.nih.gov/32040503/.

20.

Wu AD, Dan W, Zhang Y, Vemaraju S, Upton BA, Lang RA, et al. Opsin 3–Gas promotes airway smooth muscle relaxation modulated by G protein receptor kinase 2. Am J Respir Cell Mol Biol. American Thoracic Society; 2021;64:59–68. Available from: https://pubmed.ncbi.nlm.nih.gov/33058732/.

21.

Regard JB, Sato IT, Coughlin SR. Anatomical Profiling of G Protein-Coupled Receptor Expression. Cell. Elsevier B.V.; 2008;135:561–71. Available from: /pmc/articles/PMC2590943/.

22.

Rosell M, Kaforou M, Frontini A, Okolo A, Chan YW, Nikolopoulou E, et al. Brown and white adipose tissues: Intrinsic differences in gene expression and response to cold exposure in mice. Am J Physiol - Endocrinol Metab. 2014;306.

23.

Ondrusova K, Fatehi M, Barr A, Czarnecka Z, Long W, Suzuki K, et al. Subcutaneous white adipocytes express a light sensitive signaling pathway mediated via a melanopsin/TRPC channel axis. Sci Rep. Nature Publishing Group; 2017;7:1–9. Available from: https://www.nature.com/scientificreports/.

24.

Zhang KX, D’Souza S, Upton BA, Kernodle S, Vemaraju S, Nayak G, et al. Violet-light suppression of thermogenesis by opsin 5 hypothalamic neurons. Nature. Nature Research; 2020;585:420–5. Available from: https://doi.org/10.1038/s41586-020-2683-0.

25.

Opperhuizen AL, Stenvers DJ, Jansen RD, Foppen E, Fliers E, Kalsbeek A. Light at night acutely impairs glucose tolerance in a time-, intensity- and wavelength-dependent manner in rats. Diabetologia. Springer Verlag; 2017;60:1333–43. Available from: https://pubmed.ncbi.nlm.nih.gov/28374068/.

26.

Fonken LK, Nelson RJ. The effects of light at night on circadian clocks and metabolism. Endocr Rev. Endocrine Society; 2014. p. 648–70. Available from: https://pubmed.ncbi.nlm.nih.gov/24673196/.

27.

Laermans J, Depoortere I. Chronobesity: Role of the circadian system in the obesity epidemic. Obes Rev. Blackwell Publishing Ltd; 2016;17:108–25. Available from: https://pubmed.ncbi.nlm.nih.gov/26693661/.

28.

Milligan G, Alvarez-Curto E, Hudson BD, Prihandoko R, Tobin AB. FFA4/GPR120: Pharmacology and Therapeutic Opportunities. Trends Pharmacol Sci. Elsevier Ltd; 2017. p. 809–21. Available from: https://pubmed.ncbi.nlm.nih.gov/28734639/.

29.

Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. Nat Med; 2005;11:90–4. Available from: https://pubmed.ncbi.nlm.nih.gov/15619630/.

30.

Cartoni C, Yasumatsu K, Ohkuri T, Shigemura N, Yoshida R, Godinot N, et al. Taste preference for fatty acids is mediated by GPR40 and GPR120. J Neurosci. Society for Neuroscience; 2010;30:8376–82. Available from: /pmc/articles/PMC6634626/.

31.

Matsumura S, Eguchi A, Mizushige T, Kitabayashi N, Tsuzuki S, Inoue K, et al. Colocalization of GPR120 with phospholipase-Cβ2 and α-gustducin in the taste bud cells in mice. Neurosci Lett. Neurosci Lett; 2009;450:186–90. Available from: https://pubmed.ncbi.nlm.nih.gov/19071193/.

32.

Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan WQ, et al. GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects. Cell. Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, CA 92093, USA.; 2010;142:687–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20813258.

33.

Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, Yengo L, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature. 2012;483:350–4.CrossRef

34.

Quesada-López T, Cereijo R, Turatsinze JV, Planavila A, Cairó M, Gavaldà-Navarro A, et al. The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. Nat Commun. Nature Publishing Group; 2016;7.

35.

Schilperoort M, Dam AD, Hoeke G, Shabalina IG, Okolo A, Hanyaloglu AC, et al. The GPR 120 agonist TUG ‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat. EMBO Mol Med. EMBO; 2018;10.

36.

Quesada-López T, Gavaldà-Navarro A, Morón-Ros S, Campderrós L, Iglesias R, Giralt M, et al. GPR120 controls neonatal brown adipose tissue thermogenic induction. Am J Physiol Metab. NLM (Medline); 2019;317:E742–50. Available from: https://www.physiology.org/doi/https://doi.org/10.1152/ajpendo.00081.2019.

37.

Husted AS, Ekberg JH, Tripp E, Nissen TAD, Meijnikman S, O’Brien SL, et al. Autocrine negative feedback regulation of lipolysis through sensing of NEFAs by FFAR4/GPR120 in WAT. Mol Metab. Elsevier GmbH; 2020;42. Available from: https://pubmed.ncbi.nlm.nih.gov/33091626/.

38.

Liu D, Costanzo A, Evans MDM, Archer NS, Nowson C, Duesing K, et al. Expression of the candidate fat taste receptors in human fungiform papillae and the association with fat taste function. Br J Nutr. Cambridge University Press; 2018;120:64–73. Available from: https://pubmed.ncbi.nlm.nih.gov/29936924/.

39.

Running CA, Craig BA, Mattes RD. Oleogustus: The unique taste of fat. Chem Senses. Oxford University Press; 2015;40:507–16. Available from: https://pubmed.ncbi.nlm.nih.gov/26142421/.

40.

Bjursell M, Admyre T, Göransson M, Marley AE, Smith DM, Oscarsson J, et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol - Endocrinol Metab. Am J Physiol Endocrinol Metab; 2011;300. Available from: https://pubmed.ncbi.nlm.nih.gov/20959533/.

41.

Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. Nature Publishing Group; 2013;4:1829. Available from: /pmc/articles/PMC3674247/.

42.

Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. Blackwell Publishing Ltd; 2017. p. 29–41. Available from: https://pubmed.ncbi.nlm.nih.gov/27928878/.

43.

Venegas DP, De La Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. Frontiers Media S.A.; 2019. p. 277. Available from: https://www.frontiersin.org.

44.

Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SEK, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. BMJ Publishing Group; 2015;64:1744–54. Available from:https://doi.org/10.1136/gutjnl-2014-307913.

45.

Chambers ES, Byrne CS, Aspey K, Chen Y, Khan S, Morrison DJ, et al. Acute oral sodium propionate supplementation raises resting energy expenditure and lipid oxidation in fasted humans. Diabetes, Obes Metab. Blackwell Publishing Ltd; 2018;20:1034–9. Available from: https://pubmed.ncbi.nlm.nih.gov/29134744/.

46.

Hu J, Kyrou I, Tan BK, Dimitriadis GK, Ramanjaneya M, Tripathi G, et al. Short-chain fatty acid acetate stimulates adipogenesis and mitochondrial biogenesis via GPR43 in brown adipocytes. Endocrinology. Endocrine Society; 2016;157:1881–94. Available from: https://pubmed.ncbi.nlm.nih.gov/26990063/.

47.

Sahuri-Arisoylu M, Brody LP, Parkinson JR, Parkes H, Navaratnam N, Miller AD, et al. Reprogramming of hepatic fat accumulation and “browning” of adipose tissue by the short-chain fatty acid acetate. Int J Obes. Nature Publishing Group; 2016;40:955–63. Available from: https://www.nature.com/ijo.

48.

Avau B, Bauters D, Steensels S, Vancleef L, Laermans J, Lesuisse J, et al. The gustatory signaling pathway and bitter taste receptors affect the development of obesity and adipocyte metabolism in mice. PLoS One. Public Library of Science; 2015;10. Available from: https://pubmed.ncbi.nlm.nih.gov/26692363/.

49.

Ning X, He J, Shi X, Yang G. Regulation of adipogenesis by quinine through the ERK/S6 pathway. Int J Mol Sci. MDPI AG; 2016;17. Available from: https://pubmed.ncbi.nlm.nih.gov/27089323/.

50.

Cancello R, Micheletto G, Meta D, Lavagno R, Bevilacqua E, Panizzo V, et al. Expanding the role of bitter taste receptor in extra oral tissues: TAS2R38 is expressed in human adipocytes. Adipocyte. Taylor and Francis Inc.; 2020;9:7–15. Available from: https://pubmed.ncbi.nlm.nih.gov/31900035/.

51.

Luo M, Ni K, Jin Y, Yu Z, Deng L. Toward the identification of extra-oral TAS2R agonists as drug agents for muscle relaxation therapies via bioinformatics-aided screening of bitter compounds in traditional Chinese medicine. Front Physiol. Frontiers Media S.A.; 2019. Available from: https://pubmed.ncbi.nlm.nih.gov/31379593/.

52.

Kimura S, Kato E. TAS2R expression profile in brown adipose, white adipose, skeletal muscle, small intestine, liver and common cell lines derived from mice. Gene Reports. Elsevier Inc; 2020;20:100763.

53.

Kochem M. Type 1 Taste Receptors in Taste and Metabolism. Ann Nutr Metab. S. Karger AG; 2017;70:27–36. Available from: https://pubmed.ncbi.nlm.nih.gov/28903111/.

54.

Murovets VO, Bachmanov AA, Zolotarev VA. Impaired glucose metabolism in mice lacking the Tas1r3 taste receptor gene. PLoS One. Public Library of Science; 2015;10. Available from: https://www.pubmed.ncbi.nlm.nih.gov/26107521/.

55.

Glendinning JI, Gillman J, Zamer H, Margolskee RF, Sclafani A. The role of T1r3 and Trpm5 in carbohydrate-induced obesity in mice. Physiol Behav. Physiol Behav; 2012;107:50–8. Available from: https://pubmed.ncbi.nlm.nih.gov/22683548/.

56.

Smith KR, Hussain T, Azari EK, Steiner JL, Ayala JE, Pratley RE, et al. Disruption of the sugar-sensing receptor T1R2 attenuates metabolic derangements associated with diet-induced obesity. Am J Physiol - Endocrinol Metab. American Physiological Society; 2016;310:E688–98. Available from: https://pubmed.ncbi.nlm.nih.gov/26884387/.

57.

Simon BR, Learman BS, Parlee SD, Scheller EL, Mori H, Cawthorn WP, et al. Sweet taste receptor deficient mice have decreased adiposity and increased bone mass. PLoS One. Public Library of Science; 2014;9. Available from: https://pubmed.ncbi.nlm.nih.gov/24466105/.

58.

Masubuchi Y, Nakagawa Y, Ma J, Sasaki T, Kitamura T, Yamamoto Y, et al. A Novel Regulatory Function of Sweet Taste-Sensing Receptor in Adipogenic Differentiation of 3T3-L1 Cells. PLoS One. PLoS One; 2013;8. Available from: https://pubmed.ncbi.nlm.nih.gov/23336004/.

59.

Nakajima A, Nakatani A, Hasegawa S, Irie J, Ozawa K, Tsujimoto G, et al. The short chain fatty acid receptor GPR43 regulates inflammatory signals in adipose tissue M2-type macrophages. Takahashi N, editor. PLoS One. Public Library of Science; 2017;12:e0179696. Available from: https://dx.plos.org/https://doi.org/10.1371/journal.pone.0179696.

60.

Hong Y-H, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, Gotoh C, et al. Acetate and Propionate Short Chain Fatty Acids Stimulate Adipogenesis via GPCR43. Endocrinology. Oxford Academic; 2005;146:5092–9. Available from: https://academic.oup.com/endo/article/146/12/5092/2499972.

61.

Frost G, Cai Z, Raven M, Otway DT, Mushtaq R, Johnston JD. Effect of short chain fatty acids on the expression of free fatty acid receptor 2 (Ffar2), Ffar3 and early-stage adipogenesis. Nutr Diabetes. Nature Publishing Group; 2014;4.

62.

Muredda L, Kępczyńska MA, Zaibi MS, Alomar SY, Trayhurn P. IL-1β and TNFα inhibit GPR120 (FFAR4) and stimulate GPR84 (EX33) and GPR41 (FFAR3) fatty acid receptor expression in human adipocytes: implications for the anti-inflammatory action of n-3 fatty acids. Arch Physiol Biochem. Taylor and Francis Ltd; 2018;124:97–108. Available from: https://pubmed.ncbi.nlm.nih.gov/28835131/.

63.

64.

Nagasaki H, Kondo T, Fuchigami M, Hashimoto H, Sugimura Y, Ozaki N, et al. Inflammatory changes in adipose tissue enhance expression of GPR84, a medium-chain fatty acid receptor: TNFα enhances GPR84 expression in adipocytes. FEBS Lett. FEBS Lett; 2012;586:368–72. Available from: https://pubmed.ncbi.nlm.nih.gov/22245676/.

65.

Montgomery MK, Osborne B, Brandon AE, O’Reilly L, Fiveash CE, Brown SHJ, et al. Regulation of mitochondrial metabolism in murine skeletal muscle by the medium-chain fatty acid receptor Gpr84. FASEB J. John Wiley and Sons Inc.; 2019;33:12264–76. Available from: https://pubmed.ncbi.nlm.nih.gov/31415180/.

66.

67.

Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: New agents, targets and indications. Nat Rev Drug Discov. Nature Publishing Group; 2017;16:829–42. Available from: https://pubmed.ncbi.nlm.nih.gov/29075003/.

68.

Suchý T, Zieschang C, Popkova Y, Kaczmarek I, Weiner J, Liebing AD, et al. The repertoire of Adhesion G protein-coupled receptors in adipocytes and their functional relevance. Int J Obes. Springer Nature; 2020;44:2124–36. Available from: https://pubmed.ncbi.nlm.nih.gov/32203115/.

69.

Forbes S, Stafford S, Coope G, Heffron H, Real K, Newman R, et al. Selective FFA2 agonism appears to act via intestinal PYY to reduce transit and food intake but does not improve glucose tolerance in mouse models. Diabetes. American Diabetes Association Inc.; 2015;64:3763–71. Available from: https://diabetes.diabetesjournals.org/content/64/11/3763.

70.

Hudson BD, Due-Hansen ME, Christiansen E, Hansen AM, Mackenzie AE, Murdoch H, et al. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem. Elsevier; 2013;288:17296–312. Available from: http://www.jbc.org/article/S0021925820458740/fulltext.

71.

Hansen AH, Sergeev E, Bolognini D, Sprenger RR, Ekberg JH, Ejsing CS, et al. Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. J Med Chem. American Chemical Society; 2018;61:9534–50. Available from: https://pubs.acs.org/sharingguidelines.

72.

Oh DY, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. Nature Publishing Group; 2014;20:942–7. Available from: https://pubmed.ncbi.nlm.nih.gov/24997608/.

73.

Bianchini G, Nigro C, Sirico A, Novelli R, Prevenzano I, Miele C, et al. A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice. Biomed Pharmacother. Elsevier Masson s.r.l.; 2021;139:111613.

74.

Carullo G, Mazzotta S, Vega-Holm M, Iglesias-Guerra F, Vega-Perez JM, Aiello F, et al. GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery. J Med Chem. American Chemical Society; 2021. p. 4312–32. Available from: https://pubmed.ncbi.nlm.nih.gov/33843223/.

75.

Brum MCB, Filho FFD, Schnorr CC, Bottega GB, Rodrigues TC. Shift work and its association with metabolic disorders. Diabetol Metab Syndr. BioMed Central Ltd.; 2015. Available from: /pmc/articles/PMC4436793/.

76.

Ozdeslik RN, Olinski LE, Trieu MM, Oprian DD, Oancea E, Yau -W. Human nonvisual opsin 3 regulates pigmentation of epidermal melanocytes through functional interaction with melanocortin 1 receptor; Available from: https://doi.org/10.1073/pnas.1902825116.

77.

Hoch M, Eberle AN, Wagner U, Bussmann C, Peters T, Peterli R. Expression and Localization of Melanocortin-1 Receptor in Human Adipose Tissues of Severely Obese Patients*. Obesity. John Wiley & Sons, Ltd; 2007;15:40–9. Available from: https://doi.org/10.1038/oby.2007.525.

Title: Metabolic responses of light and taste receptors – unexpected actions of GPCRs in adipocytes
Authors: Onyinye Nuella Ekechukwu
Mark Christian
Publication date: 01-02-2022
Publisher: Springer US
Keywords: Lipolysis
Lipolysis
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 1/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-021-09667-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

The endocrine adipose organ

Adipogenic progenitors in different organs: Pathophysiological implications

Leptin, the brain and energy homeostasis: From an apparently simple to a highly complex neuronal system

Intercellular and interorgan crosstalk through adipocyte extracellular vesicles

The endocrine role of brown adipose tissue: An update on actors and actions

Leptin as a key regulator of the adipose organ

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage